|Bid||41.80 x 1000|
|Ask||45.95 x 4000|
|Day's Range||43.15 - 45.10|
|52 Week Range||33.30 - 61.25|
|PE Ratio (TTM)||27.71|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.22|
Supernus Pharmaceuticals on Wednesday reported income of 57 cents per share on sales of $99.5 million for its second quarter.
Major equity indexes took a break on Wednesday, but the stock market bulls continued to pile into top-rated internet content stocks.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 9:00 AM Eastern ...
Supernus (SUPN) delivered earnings and revenue surprises of 29.55% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rockville, Maryland-based company said it had net income of 57 cents. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
Total revenue of $99.5 million, a 31% increase over 2017 Net product sales of $97.0 million, a 32% increase over 2017 Operating earnings of $35.7 million, a 37% increase over 2017 Diluted earnings per ...
Short interest is moderately high for SUPN with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $1.38 billion over the last one-month into ETFs that hold SUPN are among the lowest of the last year and appear to be slowing.
ROCKVILLE, Md., July 25, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Short interest is moderately high for SUPN with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 7. The net inflows of $5.60 billion over the last one-month into ETFs that hold SUPN are among the highest of the last year, but the rate of growth is slowing.
Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Dr. Carrolee Barlow, M.D., Ph.D., has joined Supernus’ Board of Directors effective immediately. Dr. Barlow is an expert in neuroscience and neurodegeneration, and is currently the Chief Executive Officer of the Parkinson’s Institute and Clinical Center, Sunnyvale, California. “Dr. Barlow’s deep expertise in neurology, as well as her strategic, operational and academic experience, will add significant value to our Board and to the Company,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
Attractive stocks have exceptional fundamentals. In the case of Supernus Pharmaceuticals Inc (NASDAQ:SUPN), there’s is a financially-robust company with a strong track record and a buoyant growth outlook. Below isRead More...
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on IRWD sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com observes the recent performance of Horizon Pharma PLC (NASDAQ: HZNP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lipocine Inc. (NASDAQ: LPCN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).
NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Supernus ...
NEW YORK , June 1, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities law violations at Supernus Pharmaceuticals, Inc. ("Supernus" ...
ROCKVILLE, Md., May 30, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market cap had gained 373% between 2013 and 2017.
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT). The S&P 500 Growth index generated a three-year and five-year annualized return of 13.2% and 15.2%, respectively. These returns compare to the S&P 500 (SPY) at 10.7% and 13% for the same timespan, respectively. The S&P 500 Growth index generated YTD (year-to-date) return of 5.5%, compared to the S&P 500 at 1.5%. The S&P 500 Growth has 41% exposure to information technology, compared to the S&P 500 at 24.8%. ...
Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.